Professor David Callen
Research Interests
Professor David Callen is Director of the Centre for Personalised Cancer Medicine which has a cross-disciplinary and membership and a focus on translational outcomes. See http://www.adelaide.edu.au/cpcm/ for further details.
He is also Postgraduate Coordinator for the School of Medicine.
The research interests of David Callen are the un-ravelling of molecular pathways that provide new therapeutic approaches to treating cancers. His research at the Cancer Therapeutics Laboratory is focussed in two areas, the Breast Cancer Genetics Group, headed by Dr Rachel Suetani, and the Sarcoma Research Group, headed by Dr Paul Neilsen. This research involves collaboration with groups both within Australia and overseas and is funded from three current NHMRC grants.
David Callen has published over 250 peer-reviewed research articles and has an h-index of 48. Publications include those in the top medical science literature including Lancet, Cell, Science, Nature, Nature Genetics and Nature Cell Biology.
The research approach of the Cancer Therapeutics Laboratory is to use a combination of cutting edge molecular and cell biology techniques, human tumour explant models, xenografts of human cancer cell lines in mouse, and immunohistochemistry of human tumour tissue. Our group is situated in well equipped laboratories on the 3rd floor of the Hanson Institute Building behind the Medical School on Frome Road. Active collaboration with local, national and international research groups complements the research approach. The student environment is challenging with exciting projects that ensure a fulfilling and enjoyable research experience. Currently there are four PhD students and one Honours student in the group.
Major research projects for prospective research students are:
- A gene signature that predicts poor survival in breast cancer
- How does high levels of vitamin D protect against breast cancer?
- Targeted therapies for childhood bone cancers
- Development of therapies to prevent the side-effects of chemotherapy
For further details of research opportunities in the Centre for Personalised Cancer Medicine and the Cancer Therapeutics Laboratory contact Prof Callen.
Research Funding
The research of the Cancer Therapeutics Laboratory is currently funded by three NHMRC project grants and an ARC grant. Sarcoma research is funded by a grant from Cancer Care Australia and the Rainbows for Kate Foundation.
Publications
1. Neilsen PM, Pishas KI, Callen DF, and Thomas DM (2011), Targeting the p53 pathway in Ewing sarcoma, Sarcoma. 2011;2011:746939. Epub 2010 Dec 9.
2. Fullston T, Gabb B, Callen D, Ullmann R, Woollatt E, Bain S, Ropers HH, Cooper M, Chandler D, Carter K, Jablensky A, Kalaydjieva L, Gecz J (2011) Inherited balanced translocation t(9;17)(q33.2;q25.3) concomitant with a 16p13.1 duplication in a patient with schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2011 Jan 13. [Epub ahead of print]
3. Noll JE, Jeffery J, Al-Ejeh F, Kumar R, Khanna KK, Callen DF, Neilsen PM (2011) Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11. Oncogene. 2011 Oct 10 [Epub ahead of print]
4. Azad A, Jackson S, Cullinane C, Natoli AL, Neilsen PM, Callen DF, Maira SM, Hackl W, McArthur GA, Solomon B. Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells. Mol Cancer Res. 2011 Oct 18. [Epub ahead of print]
5. Lim SP, Neilsen P, Kumar R, Abell A, Callen DF (2011) The application of delivery systems for DNA methyltransferase inhibitors. BioDrugs 25: 227-42
6. Kumar R, Selth L, Schulz RB, Tay BS, Neilsen PM, Callen DF. (2011) Genome-wide mapping of ZNF652 promoter binding sites in breast cancer cells. J Cell Biochem. 112: 227-42.
7. Callen DF, Ricchardelli C, Butler M, Stapleton A, Stahl J, Kench JG, Horsfall DJ, Tilley WD, Schulz R, Nesland JM, Neilsen PM, Kumar R, Holm R (2010) Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome. Oncol Rep 23: 1045-52.
8. Sharma RK, Cheney KM, Neilsen PM, Schulz RB, Callen DF (2010) CBFA2T3-ZNF651, like CBFA2T3-ZNF652, functions as a transcriptional corepressor complex. FEBS Lett 584: 859-64.
9. Lamprecht B, Walter K, Kreher S, Kumar R, Hummel M, Lenze D, Köchert K, Bouhlel MA, Richter J, Soler E, Stadhouders R, Jöhrens K, Wurster KD, Callen DF, Harte MF, Giefing M, Barlow R, Stein H, Anagnostopoulos I, Janz M, Cockerill PN, Siebert R, Dörken B, Bonifer C, Mathas S (2010) De-repression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med, 16:571-9.
10. Kumar R, Iachini DN, Neilsen PM, Kaplan J, Michalakas J, Anderson PH, May BK, Morris HA, Callen DF (2010) Systematic characterisation of the rat and human CYP24A1 promoter . Mol Cell Endocrinol 325:46-53.
11. Parimi S, Barnes TJ, Callen DF, Prestidge CA. (2010) Mechanistic insight into cell growth, internalization, and cytotoxicity of PAMAM dendrimers. Biomacromolecules, 11:382-9.
12. Pishas K, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown M, Callen DF, Neilsen PM (2011) Nutlin-3a is a potential therapeutic for Ewing Sarcoma. Clin Cancer Res. 17: 494-504.
13. Kumar R, Neilsen PM, Crawford J, McKirdy R, Lee J, Powell JA, Saif Z, Martin JM, Lombaerts M, Cornelisse CJ, Cleton-Jansen A-M, Callen DF. (2005) FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex. Cancer Res 65:11304-11313.
14. Holm R, Knopp S, Kumar R, Lee J, Nesland JM, Tropè C, Callen DF. (2008) Expression of ZNF652, a novel zinc finger protein, in vulvar carcinomas and its relation to prognosis. J Clin Pathol. 61:59-63
15. Neilsen PM, Cheney KM, Li C-W, Chen D, Cawrse JE, Powell JA, Kumar R, Callen DF (2008) Identification of ANKRD11 as a novel p53 coactivator. J Cell Science 121:3541-52
16. Kumar R, Cheney KM, McKirdy R, Neilsen PM, Schulz RB, Lee J, Cohen J, Booker GW, Callen DF. (2008) CBFA2T3-ZNF652 corepressor complex regulates transcription of the E-box gene HEB. J Biol Chem, 283:19026-38.
17. Tischfield MA, Baris HN, Wu C, Rudolph G, Van Maldergem L, He W, Chan W-M, Andrews C, Demer JL, Robertson RL, Mackey DA, Ruddle JB, Bird TD, Gottlob I, Pieh C, Traboulsi EI, Pomeroy SL, Hunter DG, Soul JS, Newlin A, Sabol LJ, Doherty EJ, de Uzcategui CE, De Uzcategui N, Collins ML, Sener EC, Wabbels B, Hellebrand H, Meitinger T, de Berandinis T, Magli A, Schiavi C, Pastore-Trossello M, Koc F, Wong AM, Levin AV, Geraghty MT, Descartes M, Flaherty MP, Jamieson RV, Moller HU, Meuthen I, Callen DF, Kerwin J, Lindsay S, Meindl A, Gupta ML, Jr Pellman D, and Engle EC (2010) Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance. Cell, 140:74-87.
18. Kumar R, Manning J, Spendlove HE, Kremmidiotis G, McKirdy R, Lee J, Millband DN, Cheney KM, Stampfer MR, Dwivedi PP, Morris HA, Callen DF. (2006) ZNF652, a novel zinc finger protein, interacts with the putative breast tumor suppressor CBFA2T3 to repress transcription. Mol Cancer Res 4:655-65.
19. Martin J, Han C, Gordon LA, Terry A, Prabhakar S, She X, Xie G, Hellsten U, Chan YM, Altherr M, Couronne O, Aerts A, Bajorek E, Black S, Blumer H, Branscomb E, Brown NC, Bruno WJ, Buckingham JM, Callen DF, Campbell CS, Campbell ML, Campbell EW, Caoile C, Challacombe JF, Chasteen LA, Chertkov O, Chi HC, Christensen M, Clark LM, Cohn JD, Denys M, Detter JC, Dickson M, Dimitrijevic-Bussod M, Escobar J, Fawcett JJ, Flowers D, Fotopulos D, Glavina T, Gomez M, Gonzales E, Goodstein D, Goodwin LA, Grady DL, Grigoriev I, Groza M, Hammon N, Hawkins T, Haydu L, Hildebrand CE, Huang W, Israni S, Jett J, Jewett PB, Kadner K, Kimball H, Kobayashi A, Krawczyk MC, Leyba T, Longmire JL, Lopez F, Lou Y, Lowry S, Ludeman T, Manohar CF, Mark GA, McMurray KL, Meincke LJ, Morgan J, Moyzis RK, Mundt MO, Munk AC, Nandkeshwar RD, Pitluck S, Pollard M, Predki P, Parson-Quintana B, Ramirez L, Rash S, Retterer J, Ricke DO, Robinson DL, Rodriguez A, Salamov A, Saunders EH, Scott D, Shough T, Stallings RL, Stalvey M, Sutherland RD, Tapia R, Tesmer JG, Thayer N, Thompson LS, Tice H, Torney DC, Tran-Gyamfi M, Tsai M, Ulanovsky LE, Ustaszewska A, Vo N, White PS, Williams AL, Wills PL, Wu JR, Wu K, Yang J, Dejong P, Bruce D, Doggett NA, Deaven L, Schmutz J, Grimwood J, Richardson P, Rokhsar DS, Eichler EE, Gilna P, Lucas SM, Myers RM, Rubin EM and Pennacchio LA, (2004) The sequence and analysis of duplication-rich human chromosome 16. Nature 432:988-994.
Entry last updated: Friday, 23 Dec 2011
